Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine
Due to immunosuppressive treatment, COVID-19 vaccination is challenging in patients with B-cell lymphoma. We prospectively evaluated CD4, CD8 T-cell and serological responses to the COVID-19 mRNA vaccine in a cohort of patients treated for a B-cell lymphoma with anti-CD20 therapy. During lymphoma tr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1524813/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594104872075264 |
|---|---|
| author | Sylvain Lamure Sylvain Lamure Houria Hendel Chavez Marie-Ghislaine de Goër de Herve Luc-Matthieu Fornecker Bernard Drenou Caroline Jacquet Fatiha Merabet Milena Kohn Florence Quélin Angela Jackson Sylvain Choquet Rémy Duléry Yassine Taoufik Caroline Besson Caroline Besson |
| author_facet | Sylvain Lamure Sylvain Lamure Houria Hendel Chavez Marie-Ghislaine de Goër de Herve Luc-Matthieu Fornecker Bernard Drenou Caroline Jacquet Fatiha Merabet Milena Kohn Florence Quélin Angela Jackson Sylvain Choquet Rémy Duléry Yassine Taoufik Caroline Besson Caroline Besson |
| author_sort | Sylvain Lamure |
| collection | DOAJ |
| description | Due to immunosuppressive treatment, COVID-19 vaccination is challenging in patients with B-cell lymphoma. We prospectively evaluated CD4, CD8 T-cell and serological responses to the COVID-19 mRNA vaccine in a cohort of patients treated for a B-cell lymphoma with anti-CD20 therapy. During lymphoma treatment, CD4, CD8, and CD19 cell dropped. While functional-specific CD4 and CD8 T-cell responses to SARS-CoV-2 were unaffected, vaccination in patients on treatment induced low specific antibody titers, contrasting with a preserved serological response when vaccination was completed before treatment initiation. Those findings reinforce a vaccinal strategy based on completion before lymphoma treatment, with a booster administered afterward. |
| format | Article |
| id | doaj-art-d80bdc43dd5444f8bc445536be3b3048 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-d80bdc43dd5444f8bc445536be3b30482025-01-20T05:23:49ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15248131524813Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccineSylvain Lamure0Sylvain Lamure1Houria Hendel Chavez2Marie-Ghislaine de Goër de Herve3Luc-Matthieu Fornecker4Bernard Drenou5Caroline Jacquet6Fatiha Merabet7Milena Kohn8Florence Quélin9Angela Jackson10Sylvain Choquet11Rémy Duléry12Yassine Taoufik13Caroline Besson14Caroline Besson15Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Lyon, FranceService d’onco-hématologie, Hôpitaux Nord-Ouest, Villefranche-Sur-Saône, FranceLaboratoire Institut national de la santé et de la recherche médicale (INSERM) U1186, Institut Gustave Roussy, Villejuif, FranceLaboratoire Institut national de la santé et de la recherche médicale (INSERM) U1186, Institut Gustave Roussy, Villejuif, FranceService d’Hématologie, Institut de Cancérologie Strasbourg Europe, Strasbourg, FranceService d’Hématologie, Groupe Hospitalier de Mulhouse Sud Alsace, Mulhouse, FranceService d’Hématologie, Centre Hospitalier Régional Universitaire (CHRU) de Nancy, Nancy, FranceService d’Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, FranceService d’Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, FranceMaison de la Recherche Clinique, Centre Hospitalier de Versailles, Le Chesnay, FranceUniversité Paris-Saclay, Université de Versailles – Saint-Quentin-en-Yvelines (UVSQ), Inserm, Équipe “Exposome et Hérédité”, Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, France0Pitie-Salpetriere Hospital, Assistance Publique - Hôpitaux de Paris (APHP)- Sorbonne University, Paris, France1Service d’Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, Assistance Publique - Hôpitaux de Paris, Sorbonne Université, Inserm UMRs 938, Paris, FranceLaboratoire Institut national de la santé et de la recherche médicale (INSERM) U1186, Institut Gustave Roussy, Villejuif, FranceService d’Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, FranceUniversité Paris-Saclay, Université de Versailles – Saint-Quentin-en-Yvelines (UVSQ), Inserm, Équipe “Exposome et Hérédité”, Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Villejuif, FranceDue to immunosuppressive treatment, COVID-19 vaccination is challenging in patients with B-cell lymphoma. We prospectively evaluated CD4, CD8 T-cell and serological responses to the COVID-19 mRNA vaccine in a cohort of patients treated for a B-cell lymphoma with anti-CD20 therapy. During lymphoma treatment, CD4, CD8, and CD19 cell dropped. While functional-specific CD4 and CD8 T-cell responses to SARS-CoV-2 were unaffected, vaccination in patients on treatment induced low specific antibody titers, contrasting with a preserved serological response when vaccination was completed before treatment initiation. Those findings reinforce a vaccinal strategy based on completion before lymphoma treatment, with a booster administered afterward.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1524813/fullCOVID-19 vaccinelymphomaimmune responseanti-CD20chemotherapy |
| spellingShingle | Sylvain Lamure Sylvain Lamure Houria Hendel Chavez Marie-Ghislaine de Goër de Herve Luc-Matthieu Fornecker Bernard Drenou Caroline Jacquet Fatiha Merabet Milena Kohn Florence Quélin Angela Jackson Sylvain Choquet Rémy Duléry Yassine Taoufik Caroline Besson Caroline Besson Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine Frontiers in Immunology COVID-19 vaccine lymphoma immune response anti-CD20 chemotherapy |
| title | Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine |
| title_full | Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine |
| title_fullStr | Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine |
| title_full_unstemmed | Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine |
| title_short | Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine |
| title_sort | lymphoma patients treated with anti cd20 and chemotherapy display disconnected t and b cell responses to covid 19 vaccine |
| topic | COVID-19 vaccine lymphoma immune response anti-CD20 chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1524813/full |
| work_keys_str_mv | AT sylvainlamure lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT sylvainlamure lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT houriahendelchavez lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT marieghislainedegoerdeherve lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT lucmatthieufornecker lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT bernarddrenou lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT carolinejacquet lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT fatihamerabet lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT milenakohn lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT florencequelin lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT angelajackson lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT sylvainchoquet lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT remydulery lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT yassinetaoufik lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT carolinebesson lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine AT carolinebesson lymphomapatientstreatedwithanticd20andchemotherapydisplaydisconnectedtandbcellresponsestocovid19vaccine |